BioSpace News Archive

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the year ended December 31, 2021.

CureVac RNA today announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer(R).

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (FDA) regarding their Investigational New Drug (IND) and breakthrough therapy status applications.

Aptose Biosciences Inc. today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference.

Quanterix Corporation today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease.

Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel for the treatment of patients with advanced pancreatic cancer in the first-line setting (NCT05239182).

Quanterix Corporation today announced financial results for the fourth quarter and twelve months ending December 31, 2021.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today published new CNS (Central Nervous System) therapeutic data validating the growing trend toward decentralization as two-thirds of CNS survey respondents plan to execute an agile or decentralized clinical trial in 2022, an increase of more than 35 percent from last year.

Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company’s Board of Directors, effective immediately.

Talis Biomedical Corporation (“TLIS”), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report fourth quarter and full year 2021 financial and operational results on Tuesday, March 15, 2022, after market close.